These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 17912784

  • 1. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2007 Sep 24; 72(184):54208-10. PubMed ID: 17912784
    [Abstract] [Full Text] [Related]

  • 2. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2002 Oct 07; 67(194):62354-70. PubMed ID: 12369590
    [Abstract] [Full Text] [Related]

  • 3. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2010 Jun 29; 75(124):37295-9. PubMed ID: 20608285
    [Abstract] [Full Text] [Related]

  • 4. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Sep 29; 69(188):58950-3. PubMed ID: 15455477
    [Abstract] [Full Text] [Related]

  • 5. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2007 May 03; 72(85):24532-4. PubMed ID: 17520775
    [Abstract] [Full Text] [Related]

  • 6. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2010 Dec 20; 75(243):79296-300. PubMed ID: 21171485
    [Abstract] [Full Text] [Related]

  • 7. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Mar 18; 69(53):12794-7. PubMed ID: 15029891
    [Abstract] [Full Text] [Related]

  • 8. Schedules of controlled substances: placement of lacosamide into schedule V. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2009 May 21; 74(97):23789-90. PubMed ID: 19507328
    [Abstract] [Full Text] [Related]

  • 9. Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2007 Dec 03; 72(231):67850-2. PubMed ID: 18064769
    [Abstract] [Full Text] [Related]

  • 10. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2009 May 21; 74(97):23790-3. PubMed ID: 19507329
    [Abstract] [Full Text] [Related]

  • 11. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2005 Jun 23; 70(120):36338-44. PubMed ID: 15973789
    [Abstract] [Full Text] [Related]

  • 12. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2005 Jul 28; 70(144):43633-5. PubMed ID: 16050051
    [Abstract] [Full Text] [Related]

  • 13. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2005 Apr 04; 70(63):16935-7. PubMed ID: 15806735
    [Abstract] [Full Text] [Related]

  • 14. The ratification of the Convention on Psychotropic Substances 1971 and its transposition into national legislation in the Federal Republic of Germany.
    Schröder O.
    Bull Narc; 1982 Apr 04; 34(3-4):1-19. PubMed ID: 6926511
    [Abstract] [Full Text] [Related]

  • 15. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2008 Jul 25; 73(144):43355-7. PubMed ID: 18949877
    [Abstract] [Full Text] [Related]

  • 16. Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2003 Apr 04; 68(65):16427-30. PubMed ID: 12678045
    [Abstract] [Full Text] [Related]

  • 17. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2007 Nov 19; 72(222):64921-30. PubMed ID: 18038486
    [Abstract] [Full Text] [Related]

  • 18. Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2001 Aug 16; 66(159):42943-4. PubMed ID: 11794309
    [Abstract] [Full Text] [Related]

  • 19. Classification of three steroids as schedule III anabolic steroids under the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2009 Dec 04; 74(232):63603-10. PubMed ID: 20169675
    [Abstract] [Full Text] [Related]

  • 20. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol [(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1999 Jul 02; 64(127):35928-30. PubMed ID: 10558581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.